These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000). Author: Kohno S, Hoban D, Protekt Surveillance Study Group. Journal: J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361. Abstract: The in vitro activity of telithromycin, a new ketolide, was compared with beta-lactam antimicrobials against pathogens commonly associated with community-acquired respiratory tract infections. These pathogens were collected during 1999-2000 as part of the ongoing PROTEKT surveillance study. Globally, penicillin nonsusceptibility among Streptococcus pneumoniae (n = 3362) was 36.3%, ranging from 21.5% (Australasia) to 68.0% (Far East). Telithromycin showed higher potency (MIC90 0.12 mg/L) than beta-lactams against S. pneumoniae; 99.9% of all and 99.6% of multi-resistant isolates were susceptible to telithromycin. Among Streptococcus pyogenes isolates (n = 1485), 100% were susceptible to beta-lactams, and the telithromycin MIC50 and MIC90 were both 0.015 mg/L. Among Haemophilus influenzae (n = 2948), 16.6% produced beta-lactamase, which reduced the activity of ampicillin, cefaclor and cefprozil. 99.9% of H. influenzae were susceptible to telithromycin and the MIC range for M. catarrhalis was 0.004-0.5 mg/L. The first year results of PROTEKT confirmed high potency for telithromycin against common respiratory tract pathogens, including beta-lactam-resistant strains.[Abstract] [Full Text] [Related] [New Search]